Caplin Steriles, a subsidiary of pharmaceutical firm Caplin Point Laboratories (NSE:CAPLIPOINT, BOM:524742), secured the US Food & Drug Administration's final approval for phenylephrine hydrochloride ophthalmic solution USP 2.5% and 10%, according to a press release filed with the Indian bourses on Friday.
Phenylephrine hydrochloride ophthalmic solution, a generic version of Alcon Research's reference listed drug, is indicated to dilate the pupil of the eyes before examinations, surgery, or treatment, the release said.
Shares of the company rose 1% in recent trade.
Price (INR): â¹1315.00, Change: â¹+5.85, Percent Change: +0.45%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments